https://melaneconsulting.ch/ monthly 1.0 https://melaneconsulting.ch/services monthly 0.9 https://melaneconsulting.ch/about yearly 0.7 https://melaneconsulting.ch/blog weekly 0.8 https://melaneconsulting.ch/contact yearly 0.6 https://melaneconsulting.ch/book yearly 0.5 https://melaneconsulting.ch/blog/ai-moves-from-drug-discovery-into-routine-manufacturing-optimisation 2026-07-12 monthly 0.7 https://melaneconsulting.ch/blog/annex-22-risk-classification 2026-05-28 monthly 0.7 https://melaneconsulting.ch/blog/astrazeneca-licenses-dizal-egfr-drug-zegfrovy-for-600-million-upfront 2026-07-15 monthly 0.7 https://melaneconsulting.ch/blog/avere-therapeutics-to-go-public-via-nextcure-merger-with-320-million 2026-07-15 monthly 0.7 https://melaneconsulting.ch/blog/bora-biologics-adds-a-rockville-site-scaling-us-single-use-capacity-to 2026-07-13 monthly 0.7 https://melaneconsulting.ch/blog/celea-therapeutics-launches-with-180-million-one-of-2026-s-largest-deb 2026-07-02 monthly 0.7 https://melaneconsulting.ch/blog/fda-accepts-swiss-biotech-pharvaris-nda-for-deucrictibant-in-hereditar 2026-07-09 monthly 0.7 https://melaneconsulting.ch/blog/fda-approves-orca-bio-s-tregzi-first-regulatory-t-cell-therapy-to-cut 2026-07-05 monthly 0.7 https://melaneconsulting.ch/blog/fda-grants-accelerated-approval-to-atacicept-trutakna-for-iga-nephropa 2026-07-07 monthly 0.7 https://melaneconsulting.ch/blog/fda-proposes-rule-to-modernise-drug-manufacturing-registration 2026-07-15 monthly 0.7 https://melaneconsulting.ch/blog/genmab-and-abbvie-s-epcoritamab-hits-its-primary-endpoint-in-phase-3-r 2026-07-03 monthly 0.7 https://melaneconsulting.ch/blog/ipsen-to-acquire-swiss-biotech-memo-therapeutics 2026-07-08 monthly 0.7 https://melaneconsulting.ch/blog/life-sciences-primer 2026-07-08 monthly 0.7 https://melaneconsulting.ch/blog/lonza-expands-strategic-biologics-collaboration-with-major-us-pharma-p 2026-07-01 monthly 0.7 https://melaneconsulting.ch/blog/lonza-to-expand-commercial-adc-payload-linker-and-hpapi-capacity-at-vi 2026-07-01 monthly 0.7 https://melaneconsulting.ch/blog/medicare-begins-covering-glp-1s-for-obesity-from-1-july-50-monthly-cop 2026-07-01 monthly 0.7 https://melaneconsulting.ch/blog/annex-22-readiness-service 2026-07-01 monthly 0.7 https://melaneconsulting.ch/blog/novartis-to-acquire-myricx-bio-for-up-to-1-5-billion-for-adc-payloads 2026-07-15 monthly 0.7 https://melaneconsulting.ch/blog/peptide-cdmo-capacity-hits-a-five-year-high-cordenpharma-leads-with-a 2026-07-14 monthly 0.7 https://melaneconsulting.ch/blog/q32-bio-s-bempikibart-posts-positive-phase-2a-data-in-alopecia-areata 2026-07-15 monthly 0.7 https://melaneconsulting.ch/blog/regenxbio-completes-confirmatory-dosing-for-rgx-202-duchenne-gene-ther 2026-07-02 monthly 0.7 https://melaneconsulting.ch/blog/restructuring-wave-takeda-cuts-us-staff-in-a-1-3-billion-plan-novartis 2026-07-01 monthly 0.7 https://melaneconsulting.ch/blog/roche-discontinues-two-huntington-s-disease-programmes 2026-07-15 monthly 0.7 https://melaneconsulting.ch/blog/roche-s-divarasib-beats-lumakras-and-krazati-in-phase-3-lung-cancer 2026-07-15 monthly 0.7 https://melaneconsulting.ch/blog/switzerland-races-to-finalise-a-us-trade-deal-pharma-tariffs-capped-at 2026-07-11 monthly 0.7 https://melaneconsulting.ch/blog/takeda-and-insilico-medicine-sign-ai-drug-discovery-collaboration 2026-07-15 monthly 0.7 https://melaneconsulting.ch/blog/us-reaches-most-favored-nation-pricing-deals-with-17-large-drugmakers 2026-07-10 monthly 0.7 https://melaneconsulting.ch/blog/vertex-to-buy-crinetics-for-10-billion-its-largest-deal-ever 2026-07-06 monthly 0.7 https://melaneconsulting.ch/blog/vistagen-s-fasedienol-misses-its-primary-endpoint-in-a-phase-3-social 2026-07-03 monthly 0.7 https://melaneconsulting.ch/blog/who-holds-the-audit-trail 2026-06-11 monthly 0.7 https://melaneconsulting.ch/blog/who-qualified-the-test 2026-06-25 monthly 0.7